Fluticasone

Summary

Fluticasone (CHEMBL1201396) is an approved small-molecule anti-allergic agent targeting NR3C1; indicated across 5 conditions including chronic obstructive pulmonary disease and eosinophilic esophagitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (NR3C1)
• Indications: 5 conditions
• Clinical trials: 149
• Chemistry: 444.5 Da · C22H27F3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201396
Name	Fluticasone
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	5311101
ChEBI	CHEBI:5134
Molecular formula	C22H27F3O4S
Molecular weight	444.5
InChIKey	MGNNYOODZCAHBA-GQKYHHCASA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F

IUPAC name: S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate

ChEBI definition: A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.

Pharmacological roles (ChEBI): anti-allergic agent, anti-asthmatic drug.

Also known as: Fluticasone, fluticasone, US11554172, Compound Fluticasone-Propionate, FLUTICASONE

Patent coverage: 8,900 distinct patent families (35,433 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NR3C1	Glucocorticoid receptor	Agonist		0.9%	P04150

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glucocorticoid receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	9.82	IC50	0.15	nM	CHEMBL_ACT_28902743

Target pathways

Aggregated over 1 target gene(s): NR3C1.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	1	NR3C1
Nuclear Receptor transcription pathway	1	NR3C1
SUMOylation of intracellular receptors	1	NR3C1
PTK6 Expression	1	NR3C1
Regulation of RUNX2 expression and activity	1	NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	1	NR3C1
Potential therapeutics for SARS	1	NR3C1
Regulation of NPAS4 gene transcription	1	NR3C1

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
regulation of gluconeogenesis	1
chromatin organization	1
regulation of DNA-templated transcription	1
regulation of transcription by RNA polymerase II	1
apoptotic process	1
chromosome segregation	1
signal transduction	1
glucocorticoid metabolic process	1
response to wounding	1
gene expression	1
microglia differentiation	1
adrenal gland development	1
nuclear receptor-mediated steroid hormone signaling pathway	1
regulation of glucocorticoid biosynthetic process	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
eosinophilic esophagitis	3	MONDO:0005361	EFO:0004232
croup	3	MONDO:0005722	EFO:0007227
asthma	3	MONDO:0004979	MONDO:0004979
diabetes mellitus	1	MONDO:0005015	EFO:0000400

Clinical trials

Total trials: 149.

Phase distribution

Phase	Trials
PHASE4	51
PHASE3	39
Not specified	31
PHASE2	18
PHASE1	10

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01225913	PHASE4	RECRUITING	Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT00119158	PHASE4	COMPLETED	Combination Therapy for Atopic Dermatitis
NCT00156819	PHASE4	COMPLETED	The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
NCT00158847	PHASE4	TERMINATED	Modification Of Disease Outcome In COPD
NCT00235053	PHASE4	COMPLETED	Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID
NCT00292838	PHASE4	COMPLETED	Relative Potency of Inhaled Corticosteroids
NCT00315744	PHASE4	COMPLETED	Viapaed Study In Children And Adolescents With Asthma
NCT00363480	PHASE4	COMPLETED	Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data
NCT00404261	PHASE4	COMPLETED	Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
NCT00440687	PHASE4	COMPLETED	Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care
NCT00527826	PHASE4	COMPLETED	Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
NCT00530842	PHASE4	COMPLETED	Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
NCT00606242	PHASE4	COMPLETED	Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma
NCT00655109	PHASE4	COMPLETED	A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis
NCT00689832	PHASE4	COMPLETED	Protopic Ointment in Children Atopic Eczema
NCT00690105	PHASE4	COMPLETED	Protopic Ointment in Adult Atopic Eczema of the Face
NCT00692978	PHASE4	COMPLETED	Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate
NCT00705341	PHASE4	COMPLETED	MethaCholine Bronchoprovocation Study (MeCIS)
NCT00763529	PHASE4	COMPLETED	Elocon vs Fluticasone in Localized Psoriasis (P03197)
NCT00829257	PHASE4	COMPLETED	Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma
NCT00830505	PHASE4	COMPLETED	Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma
NCT00845598	PHASE4	WITHDRAWN	Azelastine Fluticasone Combination vs. Fluticasone
NCT00903227	PHASE4	COMPLETED	Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis
NCT01131806	PHASE4	UNKNOWN	Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01186653	PHASE4	COMPLETED	Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT01255579	PHASE4	COMPLETED	Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma
NCT01388595	PHASE4	COMPLETED	Fluticasone and Salmeterol in Allergic Rhinitis
NCT01430403	PHASE4	COMPLETED	Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
NCT01437995	PHASE4	COMPLETED	Long-acting Beta Agonist Step Down Study
NCT01520688	PHASE4	COMPLETED	Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
NCT01657487	PHASE4	UNKNOWN	Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients
NCT01696214	PHASE4	COMPLETED	A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial
NCT01741285	PHASE4	COMPLETED	Effects of QVAR in Smokers With Asthma
NCT01794780	PHASE4	COMPLETED	A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
NCT01846962	PHASE4	COMPLETED	Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis
NCT02055352	PHASE4	COMPLETED	Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
NCT02061280	PHASE4	COMPLETED	Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial
NCT02209974	PHASE4	COMPLETED	Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD
NCT02238353	PHASE4	UNKNOWN	AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)
NCT02388373	PHASE4	COMPLETED	A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

173 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
FULVESTRANT	ChEMBL + PubChem	Phase 4 (approved)	NR3C1
PODOFILOX	ChEMBL + PubChem	Phase 4 (approved)	NR3C1
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	NR3C1
ACENOCOUMAROL	ChEMBL	Phase 4 (approved)	NR3C1
ALCLOMETASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
AMCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1
AMIODARONE	ChEMBL	Phase 4 (approved)	NR3C1
APREPITANT	ChEMBL	Phase 4 (approved)	NR3C1
AURANOFIN	ChEMBL	Phase 4 (approved)	NR3C1
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	NR3C1
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
BENZBROMARONE	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE PHOSPHORIC ACID	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE VALERATE	ChEMBL	Phase 4 (approved)	NR3C1
BUDESONIDE	ChEMBL	Phase 4 (approved)	NR3C1
BUTOCONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	NR3C1
CANRENONE	ChEMBL	Phase 4 (approved)	NR3C1
CHLORMADINONE	ChEMBL	Phase 4 (approved)	NR3C1
CICLESONIDE	ChEMBL	Phase 4 (approved)	NR3C1
CLOBETASOL PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
CLOFAZIMINE	ChEMBL	Phase 4 (approved)	NR3C1
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	NR3C1
CORTISONE	ChEMBL	Phase 4 (approved)	NR3C1
DANAZOL	ChEMBL	Phase 4 (approved)	NR3C1
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1
DEFLAZACORT	ChEMBL	Phase 4 (approved)	NR3C1
DESOGESTREL	ChEMBL	Phase 4 (approved)	NR3C1
DESONIDE	ChEMBL	Phase 4 (approved)	NR3C1
DESOXIMETASONE	ChEMBL	Phase 4 (approved)	NR3C1
DESOXYCORTICOSTERONE PIVALATE	ChEMBL	Phase 4 (approved)	NR3C1
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1
DEXTROTHYROXINE	ChEMBL	Phase 4 (approved)	NR3C1
DIENESTROL	ChEMBL	Phase 4 (approved)	NR3C1
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	NR3C1
DIFLORASONE DIACETATE	ChEMBL	Phase 4 (approved)	NR3C1
DOXORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1
DROSPIRENONE	ChEMBL	Phase 4 (approved)	NR3C1
ECONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1
EFAVIRENZ	ChEMBL	Phase 4 (approved)	NR3C1
ENZALUTAMIDE	ChEMBL	Phase 4 (approved)	NR3C1
EPLERENONE	ChEMBL	Phase 4 (approved)	NR3C1
ESTRADIOL	ChEMBL	Phase 4 (approved)	NR3C1
ESTRIOL	ChEMBL	Phase 4 (approved)	NR3C1
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	NR3C1
EXEMESTANE	ChEMBL	Phase 4 (approved)	NR3C1
FELODIPINE	ChEMBL	Phase 4 (approved)	NR3C1
FLUDROCORTISONE	ChEMBL	Phase 4 (approved)	NR3C1
FLUNISOLIDE	ChEMBL	Phase 4 (approved)	NR3C1
FLUOCINOLONE ACETONIDE	ChEMBL	Phase 4 (approved)	NR3C1
FLUOCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1
FLUOROMETHOLONE	ChEMBL	Phase 4 (approved)	NR3C1
FLUOXYMESTERONE	ChEMBL	Phase 4 (approved)	NR3C1
FLURANDRENOLIDE	ChEMBL	Phase 4 (approved)	NR3C1
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	NR3C1
FLUTICASONE PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
GLUCAGON	ChEMBL	Phase 4 (approved)	NR3C1
HALCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1